US equities |
MU $878.84 ▼-5.63% NVDA $214.13 ▼-1.43% TSLA $354.72 ▼-2.13% AAPL $343.46 ▲+0.43% META $709.33 ▼-3.72% MSFT $529.05 ▼-1.93% SPCX $146.03 ▼-1.74% AMD $528.75 ▼-5.95%
FinancialContent

Ceapro Inc (TSV:CZO)

0.2250 UNCHANGED
Last Price Updated: 1:07 PM EDT, May 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ceapro Inc

< Previous 1 2 Next >
News headline image
Aeterna Zentaris and Ceapro Complete Merger Transaction
From Ceapro Inc.
Via GlobeNewswire
News headline image
Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update
From Ceapro Inc.
Via GlobeNewswire
News headline image
Ceapro Inc. Reports 2023 Financial Results and Operational Highlights
From Ceapro Inc.
Via GlobeNewswire
News headline image
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
From Ceapro Inc.
Via GlobeNewswire
News headline image
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
From Ceapro Inc.; Aeterna Zentaris Inc.
Via GlobeNewswire
News headline image
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
From Ceapro Inc.
Via GlobeNewswire
News headline image
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business
From Ceapro Inc.
Via GlobeNewswire
News headline image
Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris
From Ceapro Inc.
Via GlobeNewswire
News headline image
Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
From Ceapro Inc.
Via GlobeNewswire
News headline image
Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights
From Ceapro Inc.
Via GlobeNewswire
News headline image
Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
From Ceapro Inc.
Via GlobeNewswire
News headline image
Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology
From Ceapro Inc.
Via GlobeNewswire
News headline image
Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update
From Ceapro Inc.
Via GlobeNewswire
News headline image
Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise
From Ceapro Inc.
Via GlobeNewswire
News headline image
Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation
From Ceapro Inc.
Via GlobeNewswire
News headline image
Ceapro to Participate in the Virtual Investor Summer Spotlight Series
Live moderated video webcast on Wednesday, July 12th at 1:00 PM ET 
From Ceapro Inc.
Via GlobeNewswire
News headline image
Ceapro Announces Results of 2023 Shareholders’ Meeting
From Ceapro Inc.
Via GlobeNewswire
News headline image
Ceapro Inc. Reports Financial Results for First Quarter 2023 and Provides Corporate Update
From Ceapro Inc.
Via GlobeNewswire
News headline image
Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases
From Ceapro Inc.
Via GlobeNewswire
News headline image
Ceapro Announces Positive Findings Demonstrating Oat Derived Beta Glucan and Avenanthramides Promote Wound Healing and Tissue Regeneration
From Ceapro Inc.
Via GlobeNewswire
News headline image
Ceapro Inc. Appoints Michel Regnier as Senior Vice President, Technical Operations
Executive function to oversee Edmonton site technical operations with implementation of Pilot Unit for Pressurized Gas eXpanded (PGX) Technology as key mandate 
From Ceapro Inc.
Via GlobeNewswire
News headline image
Ceapro Inc. Reports Record 2022 Financial Results and Operational Highlights
From Ceapro Inc.
Via GlobeNewswire
News headline image
Ceapro Announces Data from Research Collaboration with McMaster University to be Presented at the 2023 American Thoracic Society (ATS) International Conference
Oral presentation to highlight unique results from pre-clinical studies demonstrating potential of Ceapro’s yeast beta glucan to reprogram macrophages involved in fibrotic lung diseases 
From Ceapro Inc.
Via GlobeNewswire
News headline image
Ceapro Announces Data from Research Collaboration with the Angiogenesis Foundation to be Presented at the 2023 Annual Meeting of the Wound Healing American Society
From Ceapro Inc.
Via GlobeNewswire
News headline image
Ceapro Inc. Recognized as a Top 50 TSX Venture Exchange Company
From Ceapro Inc.
Via GlobeNewswire
News headline image
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
Via ACCESSWIRE
News headline image
Ceapro to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast on Wednesday, January 18th at 3:00 PM ET 
From Ceapro Inc.
Via GlobeNewswire
News headline image
Ceapro Announces Grant of Stock Options
From Ceapro Inc.
Via GlobeNewswire
News headline image
Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1/2a Human Clinical Trial Assessing Avenanthramide Tablets
From Ceapro Inc.
Via GlobeNewswire
News headline image
Ceapro Inc. Reports 2022 Third Quarter and Nine-Month Financial Results and Operational Highlights
From Ceapro Inc.
Via GlobeNewswire
< Previous 1 2 Next >